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Abstract
Background: Due to the high prevalence of depression, it is clinically relevant to improve the early identification
and assessment of depressive episodes. The main objective of the present study was to examine the psychometric
properties of the IDS-SR30 (Self-rated Inventory of Depressive Symptomatology) in a large Spanish sample of
depressive patients.
Methods: This prospective, naturalistic, multicenter, nationwide epidemiological study conducted in Spain included
1595 adult patients (65.3% females) with a DSM-IV Major Depressive Disorder (MDD. IDS-SR30 and the Hamilton
Depression Rating Scale (HDRS, 21 items)were administered to the sample. Data was collected during 2 routine
visits. The second assessment was carried out after 10 ± 2 weeks after first assessment.
Results: The IDS-SR30 showed good internal consistency (a = 0.94) and high item total correlations (≥ 0.50) were
found in 70% of the items. The convergent validity was 0.85. Results of the principal component analysis (PCA) and
confirmatory factor analyses (CFA) showed that a three factor model (labelled mood/cognition, anxiety/somatic
and sleep) is adequate for the current sample.
Conclusions: The Spanish version of the IDS-SR30 seems a reliable, valid and useful tool for measuring depression
symptomatology in Spanish population.
Background
Depression is one of the most common diagnosis, with
nearly 17% of the adult population in the community
meeting criteria for major depressive disorder (MDD)
during their lifetime [1] and approximately 7% experien-
cing MDD during a 12-month period [2]. Among pri-
mary care patients depression rates are higher due to
the association of chronic disorders [3] Recent epide-
miological studies in Spain show prevalences in primary
care settings that range from 9 to 29% [4-6].
Due to the high prevalence of this disorder, it is clini-
cally relevant to improve the early identification and
assessment of depressive episodes. Thus reliable, valid
and brief instruments for the screening of depression
are highly required [7].
There are several accepted clinician-rated and patient
self-reported measures of depressive symptoms. The
most commonly clinician-rated scales used both in the
clinical and research context are the 17, 21, 24, 28, and
31-item versions of the Hamilton Rating Scale for
Depression (HDRS) [8], and the Montgomery-Asberg
Scale (MADRS) [9]. Among the most frequently used
self-reports we find the 13 and 21-item version of the
Beck Depression Inventory (BDI) [10], the Zung Depres-
sion Rating Scale [11], The Carroll Rating Scale (CRS)
[12], and the Patient Health Questionnaire-9 (PHQ-9)
[13].
New scales for the assessment of depressive symptoms
are continuously designed in order to improve the psy-
chometric deficits of the existing instruments. Despite
the increasing availability of these new tools, the
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published back in 1960 [8], remains the most used
instrument in clinical setti n g s .H o w e v e r ,s o m ea u t h o r s
have criticized the incomplete assessment of depressive
symptoms as well as the psychometric deficits of this
widely used scale [14,15].
The Inventory of Depressive Symptomatology (IDS)
[14,16] is an assessment tool that can be used to screen
or assess the severity of depression and is widely used in
large national and international multicentre studies and
clinical trials [17-21]. The time frame for assessing
symptom severity is usually a seven-day period prior to
the evaluation. The IDS is available in two versions: a
clinician-rated (IDS-C) and a self-report (IDS-SR) scale.
Both versions require minimal training and are sensitive
to changes with medication, psychotherapy, or somatic
treatments, making them useful for both research and
clinical purposes. These scales have been translated into
different languages (German, French, Italian, Chinese...)
and a psychometric validation have been published in
some of these versions [14,22-26].
The IDS was developed to provide equivalent weight-
ings (0-3) for each symptom item, clearly stated anchors
that estimate the frequency and severity of symptoms
(including all the DSM-IV criteria required to diagnose
a major depressive episode) as well as matched clinician
and patient ratings [14,16,27,24]. A 16-item version was
later developed and have been examined in adult and
young population [28,29].
The self-rated IDS (IDS-SR30), the IDS clinician ver-
sion (IDS-C), and the Quick Inventory of Depressive
Symptomatology (QIDS) (both clinician and self-rated)
include items that rate the nine symptoms domain used
to define a major depressive episode (DSM-IV criteria).
The IDS includes additional items to define melancholic
and atypical symptom features, as well as commonly
symptoms associated to depression (irritability, anxiety).
During the development of the original version, the
item-selection of the IDS was aligned with the DSM cri-
teria and other existing depression scales. Furthermore,
symptoms of the anxious and melancholic subtypes of
depression and other atypical symptoms were included.
The selection process was supported by clinical experts
and by patients [16]. In its final form, the IDS is com-
posed by 30 items and the total score range from 0 to
84. All items are rated on a scale from 0 (symptom is
not present) to 3 (strongest impairment). In the self-
rated version (IDS-SR) a cut-off-point of 18 or above
indicates the presence of clinical relevant depressive
symptomatology [14].
There is published evidence of acceptable psycho-
metric properties for the IDS in the evaluation of
depressive outpatients [14,27,24] and inpatients [22].
There is also a substantial correlation between total
scores of the IDS-C30, the IDS-SR30 and the HDRS17 .
The IDS scores have been useful to differentiate endo-
genous from non-endogenous depressions [30] and dys-
thymic disorder from major depressive disorder [16].
The aim of this study is to assess the psychometric
properties of the Spanish version of the IDS (self-report)
using the Hamilton Depression Rating Scale (HDRS) as
a gold standard to detect the presence of a single or
recurrent major depressive episode and to determine
depressive symptoms severity.
Methods
Study design, sampling and recruitment
In the present study we utilized the RESIST data set.
The RESIST was a prospective, naturalistic, multicenter,
nationwide epidemiological study. The main objective of
the RESIST study was to compare residual symptoms
between early and late remission in a large sample of
depressive psychiatric outpatients in daily routine prac-
tice [31]. A regionally stratified sample of 400 psychia-
trists was selected to participate in the study. They were
proportionally distributed by regions within Spain’s1 7
regional communities. Each participant was asked to
recruit 4 or 5 eligible outpatients. Patients were eligible
for the study if they were 18 years or older, they met
MDD diagnoses according to DSM-IV criteria and they
had 6-8 weeks of antidepressant treatment.
Participants
A total of 1870 patients were initially recruited. 275
patients were excluded in the final analysis due to different
reasons: change of treatment (9.1%), patients without sec-
ond assessment (3.6%) incomplete or missing data (1.9%).
Finally 1595 patients were included in the analysis.
Procedure
Data collection took place from February to June 2009
after receiving the approval of the Clinical Research
Ethics Committee of the Teknon Foundation. Data was
collected during 2 routine visits after obtaining written
consent from patients. As the RESIST study was origin-
ally designed to evaluate the residual symptoms of
depression, it was required that patients had been trea-
ted with antidepressant at least 6 weeks to have depres-
sive patients in remission at first assessment.
Assessments were carried out after 6-8 weeks of antide-
pressant treatment and at 10 ± 2 weeks after first assess-
ment. Treatment with any antidepressant was allowed
by the study protocol. The antidepressant prescribed
and the dose was entirely at the discretion of the psy-
chiatrist. Change of treatment resulted in exclusion
f r o mt h es t u d y .I n t e r v i e w sw e r ed o n eb yc l i n i c a lp s y -
chiatrists. Self-reports were completed on the same day
during the clinical interview.
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Case report form at first assessment was fulfilled by the
psychiatrist and included the criteria of DSM-IV for
major depressive episode that patients should meet. It
included also collection of data about sociodemographic
characteristics (age, gender, marital status, employment
status, educational level, residence environment), and
clinical features of the depressive disorder (age of first
depressive episode, duration of episode, number of pre-
vious episodes, DSM-IV-TR comorbid psychiatric diag-
noses and comorbid medical diseases).
The Spanish translation of the Self-rated Inventory of
Depressive Symptomatology (IDS- SR30) [14] was
obtained from the authors and available on the website
http://www.ids-qids.org. There was a South American
version that we adapted to the current use of the lan-
guage in Spain.
The 21 item HDRS (Hamilton Depression Rating
Scale) [8]: is a 21 question multiple choice questionnaire
which rates the severity of symptoms observed in
depression such as low mood, agitation, anxiety and
weight loss. The clinician must choose the possible
responses to each question by interviewing the patient
and by observing the patient’s symptoms. Each item has
between 3-5 possible responses which increase in sever-
ity. The first 17 questions contribute to the total score
and question 18-21 are recorded to give further infor-
mation about depression such as if paranoid symptoms
are present. The HDRS was used as a gold standard.
Statistical analyses
The Statistical Package for Social Sciences (SPSS) ver-
sion 19.0 and the Mplus v5.1 were used to carry-out the
statistical analyses.
Factor analyses. We made use of first assessment IDS-
SR30 scores for a principal component analysis (PCA).
Then, a set of confirmatory factor analyses (CFAs)
based on the exploratory result and on the scientific lit-
erature were performed on a new data set (second
assessment scores) to find the best fitting factor struc-
ture for the instrument. Following the common assump-
tion that the ratio of subjects per variable (item) is
central for factor analysis, in both study periods we
were able to satisfy the minimum of five participants-
per-item ratio recommended by Kass and Tinsley [32].
Firstly, in order to make our results in the PCA com-
parable with those recently reported by Wardenaar [33],
we performed a Horn’s parallel analysis [34] to deter-
mine the number of factors to be retained. This is a
Monte-Carlo based simulation method, considered more
replicable than the traditional extraction techniques
(Kaiser’s criterion or Scree plot), that compares the
unrotated eigenvalues to eigenvalues from a random
sample with the same number of cases and variables.
PROMAX was used for oblique rotation. To assess the
suitability of the data for factor analysis, the Kaiser-
Mayer-Olkin’s (KMO) Measure of Sampling Adequacy
[35] was computed. KMO scores above 0.90 are consid-
ered excellent. The Bartlett’s test of Sphericity [36] was
also applied to examine the extent to which the correla-
tion matrices departed from orthogonality.
Secondly, we tested the fit of the following factor
structures: The one-factor model of Trivedi [24] with all
items loading on one depression factor, the two-factor
model of Bernstein [37] with a “depression” factor (all
items) and a “somatic” factor (items 25, 26, and 28), the
three-factor model of Rush [14] with a “mood/cogni-
tion” factor (items 5, 8, 10-14, and 17-22), an “anxiety/
arousal” factor (items 6, 7, 23-28, and 30) and a “sleep”
factor (items 1-4). Items 9, 15, 20, and 29 loaded on fac-
tors 1 and 2. Item 24 loaded on factors 2 and 3. The
recently three-factor model of Wardenaar [33] with a
“mood/cognition” factor (items 5-8, 10, 15-23, and 29),
an “anxiety/somatic” factor (11-14, 25-28) and a “sleep”
factor (items 1-4). Items 9, 24, and 30 loaded on factors
1 and 2. Finally, we also tested the fit of our exploratory
factor solution.
In ordinal items with a non-normal distribution, as the
ones in the inventory, it may be expected that the covar-
iances underestimate the true amount of relations
among variables. Therefore, we proceeded to estimate
the models from the matrix of polychoric correlations
[38]. The Mean and Variance corrected Weighted Least
Squares (WLSMV) was applied to test the fit of the fac-
tor models.
Although a model with a non significant chi-square
estimate is generally considered a good fitting model,
Hu and Bentler recommended combinational rules to
evaluate model fit [39]. Therefore, the following indices
were analysed (values in parentheses denote goodness-
of-fit standards): the Tucker-Lewis, non-normed fit
index (TLI ≥ 0.95), the comparative fit index (CFI ≥
0.95), and the root means square error of approximation
(RMSEA ≤ 0.08). We also report the Akaike’sI n f o r m a -
tion Criterion (AIC), a relative fit index especially
designed for comparing alternative factor models. The
model with the smallest AIC value has the best fit. Used
t o g e t h e r ,t h e s ei n d i c e sp r o v i d eam o r ec o n s e r v a t i v ea n d
reliable evaluation of the solution. The goodness of fit
index (GFI), the adjusted goodness of fit index (AGFI),
the relative fit index (RFI), and the normed fit index
(NFI) were not used because these indices would likely
be affected by the large sample size. Model comparisons
were performed based on a practical improvement in
model-fit approach (TLI difference ≥ 0.01) [40,41].
Internal consistency. Stratified Cronbach’s coefficient
[42] was used to assess the reliability in the presence of
subscales. Subscale internal consistency estimations
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ing CFA.
Construct validity. Pearson product-moment correla-
tions computed between the IDS-SR30 factors and the
HDRS. We took into account the Cohen’s criteria [43]
to evaluate the substantive significance of correlations
(large correlations are those > 0.50, medium correlations
are from 0.30 to 0.49, and small correlations are from
0.10 to 0.29).
Results
Sociodemographic and clinical characteristics of the
total sample are presented in table 1. The final sample
comprised 1595 patients, 553 men (34.6%) and 1042
women (65.3%) with a mean age of 47.7 years (Range
18-88). Most participants were married (61%), employed
(45%), and living in urban residence (72%). The mean
IDS-SR30 total score for the full sample was 34.85 (SD =
15) at first assessment and 15.34 (SD = 11) at second
assessment. A paired T test indicated that the difference
was statistically significant (t(1593) = 53.98, p < 0.001).
Descriptive statistics were computed for all items as
shown in Table 2. Each item was examined in terms of
mean, standard deviation, skewness, and kurtosis. Uni-
variate values approaching at least 2.0 for skewness and
7.0 for kurtosis indicate marked nonnormality [44].
Therefore, item 4 at first assessment and items 3, 4, 13/
14, 18, and 27 at second assessment had questionable
normality based on their skewness values, whereas Item
4 at first assessment and items 4 and 27 at second
assessment had questionable normality based on their
kurtosis values. With the exception of item 4, all items
obtained a corrected item-total correlation that was
higher than the rule of thumb minimum value of 0.20
[45].
Principal component analysis (PCA)
The KMO measure produced a coefficient of 0.96, indi-
cative of excellent sampling adequacy. Bartlett’st e s to f
Sphericity produced a figure of 21669.61 (P < 0.0001),
indicating that the correlation matrix was unlikely to be
an identity matrix and was therefore suitable for factor
analysis. According to the Horn’s parallel analysis three
components were extracted. Factor loadings (after rota-
tion) are displayed in Table 3. Tabachnick and Fidell
[46] suggest that, in exploratory factor analysis, an item
forms a part of a factor if its factor loading on that fac-
tor is at least 0.32 and at least 0.10 greater than its
other factor loadings. Three items (items 3, 9, and 29)
did not meet these criteria. Given that it is unlikely that
the exclusion of the three items would yield a significant
improvement in model fit in the subsequent CFAs, all
Table 1 Sociodemographic and clinical characteristics of
the study sample
Sociodemographic variables n (%)
Gender
Male 553 (34.6)
Female 1042 (65.3)
Age 47.73 (13.14)
≤ 30 155 (9.71)
31-50 780 (48.90)
> 50 660 (41.37)
Employment Status
Employed 851 (45.0)
Student 45 (2.4)
Unemployed 189 (11.8)
Housework 383 (24.0)
Retired 254 (15.9)
Civil Status
Single 315 (19.7)
Married 973 (61)
Widowed 111 (7)
Separated 196 (12.3)
Education
Incomplete Primary Studies 296 (18.6)
Complete Primary Studies 529 (33.2)
Secondary Studies 506 (31.7)
University 264 (16.6)
Lives
Living Alone 280 (17.6)
Living accompanied 1315 (82.4)
Environment
Rural residence 446 (28)
Urban residence 1149 (72)
Clinical variables M (SD)
Age First Episode 40.31 (13.15)
Duration Episode 14.2 (9.4)
Number Previous Episode
IDS-SR30 at first assessment
HDRS at first assessment
3.72 (2.9)
34.8 (15)
17.3 (8.3)
n (%)
IDS-SR30 severity
None (0-13) 200 (12.5)
Mild (14-25) 357 (22.4)
Moderate (26-38) 416 (26.1)
Severe (39-48) 347 (21.8)
Very severe (> 49) 275 (17.2)
HDRS severity
None (0-13) 200 (12.5)
Mild (14-25) 286 (17.9)
Moderate (26-38) 352 (22.1)
Severe (39-48) 626 (39.2)
Very severe (> 49) 131 (8.2)
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present three-factor solution (labelled Mood/Cognition,
Anxiety/Somatic, and Sleep), which accounted for
49.87% of the variance, was more similar to the three-
factor structure reported by Rush [14] than to the three-
factor structure recently reported by Wardenaar [33]:
there were divergences (different primary loading) in 5
items (items 3, 15, 23, 29, and 30) and 8 items (items 3,
6, 7, 11/12, 13/14, 24, 29, and 30), respectively.
Confirmatory factor analyses (CFAs)
Fit statistics for the factor models are shown in Table 4.
Although all models showed RMSEA values that are
considered acceptable (< 0.08), the one-factor and two-
factor solutions failed to provide good fit taking the
other indices into account. Considering the findings col-
lectively, all three-factor models seem adequate for the
current sample. However, as the Hu and Bentler’s guide-
lines for retaining a hypothesized model recommended,
the factor structure posited by Wardenaar [33] received
more support than the other three-factor structures
because obtained the lowest AIC value and its CFI and
TLI values reached the rule of thumb minimum value of
0.95. Furthermore, the TLI value was 0.01 greater (0.95
vs. 0.94). The correlations between the Wardenaar’s fac-
tors were all positive and statistically significant (p <
0.01): Mood/Cognition * Anxiety/Somatic = 0.76;
Mood/Cognition * Sleep = 0.78; and Anxiety/Somatic *
Sleep = 0.71. We decided to retain Wardenaar’sm o d e l
for further analyses.
Internal consistency
Prior to examining the internal consistency and conver-
gent validity of the IDS-SR30, the three items that had
cross-loadings (9, 24, and 30) were assigned to the sub-
scale with which they had the highest factor loading on
the CFA to compute the subscale scores. Thus, items 9
and 30 were assigned to the Mood/Cognition sub-scale,
Table 2 Means (M), standard deviation (SD), skewness, kurtosis, and corrected item-total correlations (rtot) for all IDS-
SR30 items
IDS-SR Items First assessment Second assessment
M (SD) Skewness Kurtosis rtot M (SD) Skewness Kurtosis rtot
1. Initial insomnia 1.41 (0.99) 0.11 -1.03 0.50 0.59 (0.68) 0.93 0.54 0.43
2. Middle insomnia 1.44 (1.08) 0.13 -1.25 0.55 0.56 (0.77) 1.26 0.91 0.52
3. Early morning awakening 1.14 (1.15) 0.45 -1.28 0.56 0.33 (0.87) 2.19 4.46 0.47
4. Sleeping to much 0.22 (0.58) 2.99 9.27 0.03 0.20 (0.47) 2.56 7.55 0.16
5. Feeling sad 1.92 (0.91) -0.33 -0.88 0.75 0.77 (0.70) 0.71 0.60 0.73
6. Feeling irritable 1.15 (0.80) 0.24 -0.49 0.49 0.54 (0.59) 0.66 0.10 0.58
7. Feeling anxious or tense 1.52 (0.78) 0.04 -0.40 0.57 0.72 (0.61) 0.48 0.54 0.63
8. Reactivity of mood 1.53 (0.93) -0.01 -0.85 0.75 0.53 (0.65) 1.02 0.84 0.70
9. Diurnal variation of mood 1.04 (0.94) 0.52 -0.70 0.29 0.55 (0.69) 1.22 1.42 0.48
10. Quality of mood 1.62 (0.93) -0.09 -0.87 0.63 0.65 (0.81) 1.14 0.66 0.68
11+12. Appetite disturbance 1.03 (0.87) 0.52 -0.40 0.57 0.36 (0.58) 1.63 2.85 0.49
13+14. Weight disturbance 1.07 (1.08) 0.57 -0.99 0.50 0.38 (0.74) 2.12 3.99 0.35
15. Concentration/decision-making 1.65 (0.87) 0.07 -0.81 0.72 0.80 (0.66) 0.47 0.25 0.68
16. Self criticism and blame 1.33 (0.89) 0.24 -0.64 0.67 0.53 (0.68) 1.23 1.47 0.68
17. Future pessimism 1.66 (0.83) 0.17 -0.77 0.72 0.83 (0.67) 0.58 0.66 0.68
18. Suicidal thoughts 0.77 (0.77) 0.77 0.15 0.62 0.21 (0.45) 2.15 5.11 0.55
19. Interest in people/activities 1.69 (0.97) 0.01 -1.12 0.76 0.68 (0.71) 0.96 1.12 0.73
20. Energy/fatigability 1.59 (0.85) 0.10 -0.67 0.75 0.77 (0.66) 0.63 0.72 0.71
21. Pleasure or enjoyment (not sex) 1.50 (0.82) 0.29 -0.52 0.74 0.67 (0.62) 0.62 0.29 0.72
22. Interest in sex 1.78 (1.03) -0.25 -1.14 0.61 1.06 (0.92) 0.62 -0.38 0.52
23. Psychomotor retardation 1.13 (0.86) 0.41 -0.48 0.68 0.42 (0.58) 1.15 0.71 0.64
24. Psychomotor agitation 0.91 (0.78) 0.69 0.25 0.44 0.38 (0.58) 1.51 2.54 0.55
25. Aches and pains 1.05 (0.70) 0.37 0.18 0.47 0.60 (0.62) 0.69 0.37 0.57
26. Sympathetic arousal 1.00 (0.77) 0.41 -0.24 0.51 0.48 (0.60) 1.00 0.76 0.56
27. Panic/phobic symptoms 0.56 (0.83) 1.32 0.80 0.36 0.19 (0.47) 2.65 7.39 0.43
28. Constipation/diarrhoea 0.57 (0.78) 1.34 1.30 0.37 0.34 (0.59) 1.93 4.27 0.32
29. Interpersonal sensitivity 1.17 (0.95) 0.44 -0.70 0.54 0.54 (0.65) 1.08 1.14 0.58
30. Leaden paralysis/Physical energy 1.38 (0.87) 0.19 -0.62 0.65 0.66 (0.69) 0.88 0.67 0.65
Note: The SE of skewness was 0.06 at first and second assessment. The SE of kurtosis was 0.12 at first and second assessment.
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IDS-SR Items Component Rush et al (1996)
a Wardenaar et al (2010)
b
1. Mood/cognition 2. Anxiety/somatic 3. Sleep
1. Initial insomnia 0.47 0.46 0.64 33
2. Middle insomnia 0.53 0.48 0.66 33
3. Early morning awakening 0.58 0.39 0.55 3 3
4. Sleeping to much 0.06 0.12 -0.64 33
5. Feeling sad 0.81 0.46 0.38 1 1
6. Feeling irritable 0.42 0.63 0.30 2 1
7. Feeling anxious or tense 0.49 0.71 0.39 2 1
8. Reactivity of mood 0.81 0.44 0.33 1 1
9. Diurnal variation of mood 0.30 0.24 0.16 - -
10. Quality of mood 0.71 0.36 0.32 1 1
11+12. Appetite disturbance 0.59 0.46 0.07 1 2
13+14. Weight disturbance 0.53 0.40 0.07 1 2
15. Concentration/decision-making 0.78 0.47 0.29 21
16. Self criticism and blame 0.72 0.48 0.22 1 1
17. Future pessimism 0.78 0.49 0.29 1 1
18. Suicidal thoughts 0.64 0.50 0.21 1 1
19. Interest in people/activities 0.84 0.46 0.31 1 1
20. Energy/fatigability 0.81 0.49 0.26 1 1
21. Pleasure or enjoyment (not sex) 0.83 0.41 0.27 1 1
22. Interest in sex 0.69 0.36 0.28 1 1
23. Psychomotor retardation 0.74 0.43 0.23 21
24. Psychomotor agitation 0.33 0.69 0.32 2 1/2
25. Aches and pains 0.44 0.59 0.07 2 2
26. Sympathetic arousal 0.43 0.73 0.22 2 2
27. Panic/phobic symptoms 0.28 0.63 0.04 2 2
28. Constipation/diarrhoea 0.33 0.52 0.00 2 2
29. Interpersonal sensitivity 0.55 0.52 0.09 2 1
30. Leaden paralysis/Physical energy 0.69 0.54 0.13 2 1/2
Eigenvalue (in real data) 10.89 1.75 1.33
Eigenvalue (randomly generated) 1.25 1.22 1.19
Factor loadings and eigenvalues.
Note: IDS-SR = Inventory of Depressive Symptomatology Self Report. Boldface indicates the primary loading for each item.
a Components on which each item had its highest loading in PCA results by Rush et al (1996). An underlined number indicates that the item loads on a different
component in this study.
b Components on which each item had its highest loading in PCA results by Wardenaar et al (2010). An underlined number indicates that the item loads on a
different component in this study.
Table 4 CFA of five factor models of the IDS-SR30 in the follow-up dataset (n = 1594)
Model Source Df c
2 TLI CFI RMSEA (90% CI) AIC
1-factor e.a. Trivedi et al. (2004) 350 3793.5 0.93 0.94 0.079 (0.076-0.081) 70462.8
2-factor Bernstein et al. (2006) 347 3692.2 0.93 0.94 0.078 (0.076-0.080) 70339.9
3-factor Rush et al. (1996) 342 3214.3 0.94 0.95 0.073 (0.070-0.075) 70018.2
3-factor Wardenaar et al. (2010) 344 2774.2 0.95 0.96 0.067 (0.064-0.069) 69926.9
3-factor PCA, present study 344 3245.4 0.94 0.95 0.073 (0.070-0.075) 69928.3
Note: IDS-SR30 = Inventory of Depressive Symptomatology Self Report; Df = degrees of freedom; CFI = Comparative Fit Index; TLI = Tucker-Lewis Index; RMSEA =
Root Mean Square Error of Approximation; 90% CI = 90% confidence interval of the RMSEA. AIC = Akaike Information Criteria.
Indices that indicate the best model fit are printed in bold font.
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sub-scale.
The results of the reliability analysis are shown in
table 5. The stratified overall Cronbach’s coefficient was
0.94 at first and second assessment. Cronbach’s a coeffi-
cient ranged from 0.54 to 0.93 in the three subscales
derived from the Wardenaar’s factor model. If item 4
was deleted, the Cronbach’s a of the Sleep sub-scale
would be 0.73 and 0.64 at first assessment and second
assessment, respectively.
Convergent validity
The IDS-SR30 would show adequate convergent validity
if the total and subscale scores correlated significantly
w i t ht h eH D R S .A sc a nb es e e ni nT a b l e6 ,t h ec o r r e l a -
tions between Mood/Cognition, Anxiety/Somatic, Sleep,
the IDS-SR30 total score and the HDRS were all signifi-
cant and large at both assessments.
Discussion
The main conclusion of our study is that the Spanish
version of the IDS-SR has good psychometric properties
and it is a useful tool for evaluating depressive sympto-
matology in Spanish population.
The rationale for and psychometric properties of the
IDS (Clinician and Self-rated version) have been pre-
viously discussed [14,16]. Both versions of the scale
attempt to address limitations of the HDRS and
MADRS which do not cover all of the diagnostic symp-
toms criteria for Major Depressive Disorder (MDD) or
depressive subtypes (e.g. melancholic or atypical
features).
Good evidence of the correspondence between indivi-
dual items and the total IDS-SR30 score was found. All
items are consistent with the scale except for item that
measures hypersomnia that showed no correlation with
the total score. Internal consistency of the Spanish-lan-
guage version of the IDS-SR30 was good (a = 0.94).
Other adaptations and validity studies confirmed the
high consistency of this instrument: (a = 0.77) [14], (a
= 0.79) [22], (0.83) [46], (a =0 . 9 2 )[ 2 4 ] ,( a = 0.93) [25].
In our study, the correlation between the IDS-SR (total
and sub-scale scores) and the HDRS at both assessments
were strong (0.85). These results were similar compared
to previous findings [14,16,47]. This indicates a good
convergent validity. The present study used CFA to
identify the best-fitting structural model of the IDS-SR.
The unidimensional structure was not supported by
exploratory or confirmatory analisys. Although an initial
PCA indicted that our 3-factor solution was more simi-
lar to the 3-factor structure reported by Rush [14] the
CFA identifies the Wardenaar factor structure [33] as
the best fitting model of the IDS-SR30.
Our results have some implications. On the one hand
IDS-SR30 do not seem to be a unidimensional measure
of depression severity and, on the other hand those
items that measures atypical features (hypersomnia,
appetite and weight increase, interperpersonal sensitivity
and leaden paralysis) and some of the items that feature
endogenous/melancholic depression (diurnal mood var-
iation, appetite and weight decrease) seems to be the
more psychometrically problematic items. More analysis
to find out a different and more complete factorial
structure that includes depressive subtypes is needed.
The heterogeneity of patients suffering from depressive
disorders adds complexity to the study and design of
good and well suited instruments for measure depressive
symptomatology.
A strength of the present study is the large and repre-
sentative sample which makes the results generalizable
to depressive Spanish outpatients. Second, all the ana-
lyses were conducted in patients that met MDD criteria
and 6-8 weeks of antidepressant treatment and allows
us to have all the severity degrees represented. Third, a
3-factor model was displayed in the statistical analysis,
as recommended by the authors of the original version
[14]. This fact allows the comparison of the results from
similar studies. The main limitation of this study is that
we did not administered the questionnaire in primary
care. Further analysis in several settings should reveal
whether our results could be generalized to depressive
inpatients or primary care settings.
Conclusions
In conclusion, our findings from this first validation
study indicate that the Spanish version of the IDS-SR
have highly acceptable psychometric properties, corro-
borating results of the original English version [14,48]
and other studies and translations. The IDS-SR30 is a
Table 5 Cronbach’s a coefficient of the IDS-SR30 (total
and sub-scale scores)
a Mood/
Cognition
Anxiety/
Somatic
Sleep IDS-
SR30
First assessment 0.93 0.77 0.57 0.94*
Second
assessment
0.93 0.75 0.54 0.94*
Note: *Stratified-alpha Coefficient
Table 6 Correlations between the IDS-SR30 (total and
sub-scale scores) and the HDRS at first and second
assessment
HDRS Mood/
Cognition
Anxiety/
Somatic
Sleep IDS-
SR30
First assessment 0.82* 0.70* 0.70* 0.85*
Second
assessment
0.82* 0.67* 0.64* 0.85*
Note: *Correlation significant at p < 0.001
Gili et al. BMC Medical Research Methodology 2011, 11:131
http://www.biomedcentral.com/1471-2288/11/131
Page 7 of 9simple and easy-to-use tool, suitable for clinical and
research use with satisfactory properties in the Spanish
population.
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